Speaker
Mr
Jason Wu
(Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia)
Description
Plasmin (Plm) is the active form of the zymogen plasminogen (Plg), a serine protease which plays a key role in the fibrinolytic system and several other physiological activities. Physiologically, Plg/Plm activity is regulated by specific inhibitors and activators, making it an attractive therapeutic target for both traumatic bleeding and thrombotic diseases. Here we report the first crystal structure of microplasmin (the catalytic domain of Plm) in complex with a small-molecular active site inhibitor PSI-112 which is highly specific for Plm with IC50 of 0.22 µM. The crystal structure has been determined to 1.62Å, and the inhibitor binds to the substrate binding pocket with extensive additional subsite interactions. This structure may be helpful in developing a more Plm specific inhibitor as a new anti-fibrinolytic agent used to reduce bleeding complications in cardiac surgery or liver transplantation.
| Keywords | plasmin; serine protease; inhibitor; therapeutic; crystal structure |
|---|
Primary author
Mr
Jason Wu
(Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia)
Co-authors
Mrs
Davadharshini Jeevarajah
(Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia)
Dr
James Whisstock
(Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia; ARC Centre of Excellence in Structural and Functional Microbial Genomics, Monash University, Clayton, VIC 3800, Australia)
Dr
Koushi Hidaka
(Center for Frontier Research in Medicinal Science, Kyoto Pharmaceutical University, Yamashina-Ku, Kyoto 607-8412, Japan)
Dr
Ruby Law
(Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia)
Dr
Yuko Tsuda
(Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan)
